探索钠-葡萄糖共转运蛋白2抑制剂对接受放射治疗的前列腺癌患者泌尿生殖系统毒性的影响:一例病例研究及讨论
本文报道一名65岁、有2型糖尿病病史的前列腺癌患者,在接受放射治疗后数月出现出血性膀胱炎,当时正在使用钠-葡萄糖共转运蛋白2抑制剂恩格列净。停用恩格列净并启用司美格鲁肽后,其泌尿系统症状显著改善。作者认为恩格列净可能是出血性膀胱炎的潜在危险因素,据其所知这是首例此类报告。
要点
- 65岁2型糖尿病前列腺癌患者放疗后数月出现出血性膀胱炎。
- 患者当时正在使用恩格列净,作者将其列为出血性膀胱炎的潜在危险因素。
- 停用恩格列净并启用司美格鲁肽后,泌尿系统症状显著改善。
核心结论
- 作者认为恩格列净可能是该患者放疗后出血性膀胱炎的潜在危险因素,据作者所知这是首例此类报告。
研究设计与样本
- 病例报告:一名65岁、有2型糖尿病病史的前列腺癌患者接受放射治疗后出现出血性膀胱炎。
主要发现
- 患者放疗后数月出现出血性膀胱炎,当时正在使用恩格列净。
- 停用恩格列净并启用司美格鲁肽后,患者泌尿系统症状显著改善。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radiation therapy is a common treatment modality offered to patients with localized prostate cancer. It can be associated with early radiation-induced toxicities including dysuria, nocturia, frequency, urgency, spasm, and, rarely, hematuria. Early toxicities usually resolve once the treatment period has ended. Chronic toxicities are less common, and rarely, patients may experience radiation-induced hemorrhagic cystitis and hematuria months or years after radiation. We herein describe the case of a 65-year-old man with a past medical history of type-2 diabetes mellitus who experienced hemorrhagic cystitis for months following his radiation therapy. The patient was on sodium-glucose cotransporter-2 inhibitor therapy (empagliflozin), which we highlight as a potential risk factor for hemorrhagic cystitis. After cessation of Jardiance and initiation of semaglutide (GLP-1 agonist), his urinary symptoms significantly improved. To the best of our knowledge, this is the first such case reported.
引用
- Andrianu K, Works D, Christiansen A, et al. Exploring the Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Genitourinary Toxicities in Prostate Cancer Patients Undergoing Radiation Therapy: A Case Study and Discussion. Pract Radiat Oncol. 2024. PMID: 38752974. doi:10.1016/j.prro.2024.04.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。